Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy

On June 10, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab (OPDIVO; Bristol Myers Squibb, New York, NY) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine‐ and platinum‐based...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Pelosof, Lorraine, Saung, May Tun, Donoghue, Martha, Casak, Sandra, Mushti, Sirisha, Cheng, Joyce, Jiang, Xiling, Liu, Jiang, Zhao, Hong, Khazraee, Maryam, Goldberg, Kirsten B., Theoret, Marc, Lemery, Steven, Pazdur, Richard, Fashoyin‐Aje, Lola
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018317/
https://ncbi.nlm.nih.gov/pubmed/33345396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13646
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados